Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia

J Neurol Sci. 2007 Sep 15;260(1-2):240-3. doi: 10.1016/j.jns.2007.04.009. Epub 2007 May 29.

Abstract

Waldenström's macroglobulinemia (WM) is a lymphoplasmacytic disorder with associated monoclonal gammopathy. A wide variety of neuropathies can be associated with WM, but most commonly it is a mild length-dependent sensory neuropathy of unclear etiology. Rituximab is a monoclonal antibody which suppresses mature B-cell populations. It has increasingly been used in wide applications including WM, especially in those cases with severe neuropathy. The highlighted case provides an example of rituximab treatment complication in a WM patient with mild sensory neuropathy that evolved to multiple mononeuropathies with features of systemic vasculitis and unusual conversion of type I to type II cryoglobulinemia.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived
  • Cryoglobulinemia / chemically induced
  • Cryoglobulinemia / immunology
  • Cryoglobulinemia / physiopathology
  • Cyclophosphamide / therapeutic use
  • Disease Progression
  • Female
  • Humans
  • Immunologic Factors / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Methylprednisolone / therapeutic use
  • Mononeuropathies / chemically induced*
  • Mononeuropathies / immunology*
  • Mononeuropathies / physiopathology
  • Peripheral Nerves / drug effects*
  • Peripheral Nerves / immunology*
  • Peripheral Nerves / pathology
  • Rituximab
  • Sural Nerve / drug effects
  • Sural Nerve / immunology
  • Sural Nerve / pathology
  • Treatment Outcome
  • Vasculitis / chemically induced
  • Vasculitis / immunology
  • Vasculitis / physiopathology
  • Waldenstrom Macroglobulinemia / drug therapy*
  • Waldenstrom Macroglobulinemia / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunologic Factors
  • Immunosuppressive Agents
  • Rituximab
  • Cyclophosphamide
  • Methylprednisolone